Search results (1331)
« Back to PublicationsHypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine-resistance in breast cancer
Morotti M. et al, (2019), Proceedings of the National Academy of Sciences of the United States of America
An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).
Mandala M. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.
Middleton MR. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Pharmacodynamic effect of IMCgp100 (TCR CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma.
Middleton MR. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).
Fogarty G. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Progression-free survival (PFS) in unresectable melanoma patients (pts) treated with talimogene laherparepvec (T-VEC) versus granulocyte macrophage colony-stimulating factor (GM-CSF) in OPTiM.
Milhem MM. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI).
Taylor F. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR-anti-CD3, in patients with advanced melanoma.
Middleton MR. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Resensitization of uveal melanoma (UM) to immune checkpoint inhibition (ICI) by IMCgp100 (IMC).
Yang J. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Immunotherapy-related hepatitis: real-world experience from a tertiary centre
CHEUNG VINCENT. et al, (2019), Frontline Gastroenterology
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.
Mak G. et al, (2019), Br J Cancer, 120, 975 - 981
Combining conventional therapy with immunotherapy: A risky business?
Coosemans A. et al, (2019), Eur J Cancer, 113, 41 - 44
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Davies A. et al, (2019), Lancet Oncol, 20, 649 - 662
Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study.
Goswami P. et al, (2019), J Comp Eff Res, 8, 523 - 533
Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP.
Eyre TA. et al, (2019), British journal of haematology
Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work.
Robinson M. et al, (2019), J Pathol Clin Res, 5, 91 - 99
Training and accreditation standards for pathologists undertaking clinical trial work.
Rees G. et al, (2019), J Pathol Clin Res, 5, 100 - 107
Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
Morrell L. et al, (2019), BMC health services research, 19, 198 - 198
Single-cell approaches reveal novel cellular pathways for megakaryocyte and erythroid differentiation.
Psaila B. and Mead AJ., (2019), Blood, 133, 1427 - 1435
Single-cell assessment of transcriptome alterations induced by Scriptaid in early differentiated human haematopoietic progenitors during ex vivo expansion
ROBERTS IRENE. et al, (2019), Scientific Reports